51024Novel Blood Test for Early Diagnosis of Ovarian CancerClosedStudyInnovate UKAlmost 300,000 women a year are diagnosed with Ovarian cancer across the world, with the number of cases are predicted to rise by 15% over the coming decades due to a plateau in research developments and therapeutic advancements. Unfortunately, due to non-specific symptoms of this disease and the sub-optimal diagnostic test for Ovarian cancer, it is often only diagnosed in the later stages of the disease when it has already spread. More than 60% of the women with Ovarian cancer in the UK are faced with the fact that their disease is incurable at diagnosis. The current blood test for diagnosis of Ovarian cancer is unreliable, often not raised at all in women with Ovarian cancer, raised in benign unrelated conditions, or does not detect the cancer until late in the disease progression. Furthermore, there is currently no screening tool for women who are at high risk of developing Ovarian cancer. GenoME has developed a simple blood test which detects specific modifications of DNA (DNA methylation) which are present in the early stages of Ovarian cancer. This test exhibits far superior statistical power and reliability than the current Ovarian cancer test and can detect the cancer in its earliest stages, enabling women to be treated faster, improving the survival and quality of life of those affected. GenoME also aims for this test to be trialled as the world's first screening tool for women at risk of developing Ovarian cancer. This OvaME Ovarian cancer test is the first product for the company, and GenoME will not stop at just this test. We are able to apply this same technology to develop tests for not just other cancer types but also a multitude of various other diseases which have classically lacked in research and diagnostic improvements or knowledge.